Technological innovation, establishing a new system for HPV vaccine production

The HPV vaccine produced by internationally renowned pharmaceutical companies such as GSK and Merck uses traditional eukaryotic cell culture techniques, which have the disadvantages of low yield, long production cycles and high cost. The Kangleweishi team continued to tackle the problem and finally achieved technological breakthroughs. It successfully used the E. coli system to express the HPV vaccine. Compared to similar products using yeast or other eukaryotic cells, the innovative approach adopted by Kangleweishi has the advantages of high yield, a short production cycle and low cost.

E-Town Capital supports regional industry optimization, upgrading and development

In order to cultivate a group of advanced technologies and innovative products to fill gaps in the industry and introduce and support a group of high-growth, high-tech innovative enterprises and leading talent core teams, Beijing E-Town International Investment and Development Co., Ltd. (E-Town Capital for short) is committed to introducing strategic capital investment for high-tech enterprises, supporting them to become bigger and stronger, and then supporting the optimization, upgrading and development of regional industries.

So far, E-Town Capital has conducted effective communication with Kangleweishi to gain an in-depth understanding of the needs of the business, and will continue to support its development from various aspects such as with capital and industrial resources.

E-Town Capital will help a large number of partners with common values in the Beijing Venture Capital Alliance to participate in regional industry investment, and use professional institutions to experience industry insights, corporate investment, development management and other aspects to help many high-quality companies such as Kangleweishi become bigger and stronger, and find strategic investment partners that match the development of the company.